Cargando…
Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
BACKGROUND: ADJUVANT-CTONG1104 reported a favorable survival outcome from adjuvant gefitinib treatment over chemotherapy in EGFR-mutant non-small cell lung cancer (NSCLC) patients. However, heterogeneous benefit from EGFR-TKIs and chemotherapy demands further biomarker exploration for patient select...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990191/ https://www.ncbi.nlm.nih.gov/pubmed/36879350 http://dx.doi.org/10.1186/s40364-023-00470-z |
_version_ | 1784901889131806720 |
---|---|
author | Liu, Si-Yang Maggie Chen, Cunte Zhang, Yi-Kai Zhong, Wen-Zhao Wu, Yi-Long Liu, Si-Yang Li, Yangqiu |
author_facet | Liu, Si-Yang Maggie Chen, Cunte Zhang, Yi-Kai Zhong, Wen-Zhao Wu, Yi-Long Liu, Si-Yang Li, Yangqiu |
author_sort | Liu, Si-Yang Maggie |
collection | PubMed |
description | BACKGROUND: ADJUVANT-CTONG1104 reported a favorable survival outcome from adjuvant gefitinib treatment over chemotherapy in EGFR-mutant non-small cell lung cancer (NSCLC) patients. However, heterogeneous benefit from EGFR-TKIs and chemotherapy demands further biomarker exploration for patient selection. Previously, we identified certain TCR sequences with predictive value for adjuvant therapies from the CTONG1104 trial and found a relationship between the TCR repertoire and genetic variations. It remains unknown which TCR sequences could further enhance the prediction for only adjuvant EGFR-TKI. METHODS: In this study, 57 tumor and 12 tumor-adjacent samples, respectively, from gefitinib-treated patients in the CTONG1104 were collected for TCR β gene sequencing. We attempted to constitute a predictive model for prognosis and favorable adjuvant EGFR-TKI outcome for patients with early-stage NSCLC and EGFR mutations. RESULTS: The TCR rearrangements demonstrated significant prediction for overall survival (OS). A combined model of high frequent Vβ7-3Jβ2-5 and Vβ24-1Jβ2-1 with lower frequent Vβ5-6Jβ2-7 and Vβ28Jβ2-2 constituted the best value for predicting OS (P < 0.001; Hazard Ratio [HR] = 9.65, 95% confidence interval [CI]: 2.27 to 41.12) or DFS (P = 0.02; HR = 2.61, 95% CI: 1.13 to 6.03). In Cox regression analyses, when multiple clinical data were included, the risk score remained an independent prognostic predictor for OS (P = 0.003; HR = 9.49; 95% CI: 2.21 to 40.92) and DFS (P = 0.015; HR = 3.13; 95% CI: 1.25 to 7.87). CONCLUSIONS: In this study, a predictive model was constituted with specific TCR sequences for prognosis prediction and gefitinib benefit in the ADJUVANT-CTONG1104 trial. We provide a potential immune biomarker for EGFR-mutant NSCLC patients who might benefit from an adjuvant EGFR-TKI. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-023-00470-z. |
format | Online Article Text |
id | pubmed-9990191 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-99901912023-03-08 Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer Liu, Si-Yang Maggie Chen, Cunte Zhang, Yi-Kai Zhong, Wen-Zhao Wu, Yi-Long Liu, Si-Yang Li, Yangqiu Biomark Res Correspondence BACKGROUND: ADJUVANT-CTONG1104 reported a favorable survival outcome from adjuvant gefitinib treatment over chemotherapy in EGFR-mutant non-small cell lung cancer (NSCLC) patients. However, heterogeneous benefit from EGFR-TKIs and chemotherapy demands further biomarker exploration for patient selection. Previously, we identified certain TCR sequences with predictive value for adjuvant therapies from the CTONG1104 trial and found a relationship between the TCR repertoire and genetic variations. It remains unknown which TCR sequences could further enhance the prediction for only adjuvant EGFR-TKI. METHODS: In this study, 57 tumor and 12 tumor-adjacent samples, respectively, from gefitinib-treated patients in the CTONG1104 were collected for TCR β gene sequencing. We attempted to constitute a predictive model for prognosis and favorable adjuvant EGFR-TKI outcome for patients with early-stage NSCLC and EGFR mutations. RESULTS: The TCR rearrangements demonstrated significant prediction for overall survival (OS). A combined model of high frequent Vβ7-3Jβ2-5 and Vβ24-1Jβ2-1 with lower frequent Vβ5-6Jβ2-7 and Vβ28Jβ2-2 constituted the best value for predicting OS (P < 0.001; Hazard Ratio [HR] = 9.65, 95% confidence interval [CI]: 2.27 to 41.12) or DFS (P = 0.02; HR = 2.61, 95% CI: 1.13 to 6.03). In Cox regression analyses, when multiple clinical data were included, the risk score remained an independent prognostic predictor for OS (P = 0.003; HR = 9.49; 95% CI: 2.21 to 40.92) and DFS (P = 0.015; HR = 3.13; 95% CI: 1.25 to 7.87). CONCLUSIONS: In this study, a predictive model was constituted with specific TCR sequences for prognosis prediction and gefitinib benefit in the ADJUVANT-CTONG1104 trial. We provide a potential immune biomarker for EGFR-mutant NSCLC patients who might benefit from an adjuvant EGFR-TKI. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-023-00470-z. BioMed Central 2023-03-07 /pmc/articles/PMC9990191/ /pubmed/36879350 http://dx.doi.org/10.1186/s40364-023-00470-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Correspondence Liu, Si-Yang Maggie Chen, Cunte Zhang, Yi-Kai Zhong, Wen-Zhao Wu, Yi-Long Liu, Si-Yang Li, Yangqiu Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer |
title | Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer |
title_full | Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer |
title_fullStr | Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer |
title_full_unstemmed | Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer |
title_short | Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer |
title_sort | specific tcr profiles predict clinical outcome of adjuvant egfr-tkis for resected egfr-mutant non-small cell lung cancer |
topic | Correspondence |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990191/ https://www.ncbi.nlm.nih.gov/pubmed/36879350 http://dx.doi.org/10.1186/s40364-023-00470-z |
work_keys_str_mv | AT liusiyangmaggie specifictcrprofilespredictclinicaloutcomeofadjuvantegfrtkisforresectedegfrmutantnonsmallcelllungcancer AT chencunte specifictcrprofilespredictclinicaloutcomeofadjuvantegfrtkisforresectedegfrmutantnonsmallcelllungcancer AT zhangyikai specifictcrprofilespredictclinicaloutcomeofadjuvantegfrtkisforresectedegfrmutantnonsmallcelllungcancer AT zhongwenzhao specifictcrprofilespredictclinicaloutcomeofadjuvantegfrtkisforresectedegfrmutantnonsmallcelllungcancer AT wuyilong specifictcrprofilespredictclinicaloutcomeofadjuvantegfrtkisforresectedegfrmutantnonsmallcelllungcancer AT liusiyang specifictcrprofilespredictclinicaloutcomeofadjuvantegfrtkisforresectedegfrmutantnonsmallcelllungcancer AT liyangqiu specifictcrprofilespredictclinicaloutcomeofadjuvantegfrtkisforresectedegfrmutantnonsmallcelllungcancer |